Technology
Health
Pharmaceutical

Foamix

$3.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.26%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Foamix and other stocks, options, ETFs, and crypto commission-free!

About

Foamix Pharmaceuticals Ltd. Ordinary Shares, also called Foamix, is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Read More Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

Employees
81
Headquarters
Rehovot, HaMerkaz
Founded
2003
Market Cap
205.99M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
455.71K
High Today
$3.89
Low Today
$3.67
Open Price
$3.77
Volume
196.58K
52 Week High
$7.60
52 Week Low
$3.21

Collections

Technology
Health
Pharmaceutical
Therapy
2014 IPO
Asia (Non-China)
Asia

News

Seeking AlphaMar 1

Foamix Pharmaceuticals' (FOMX) CEO David Domzalski on Q4 2018 Results - Earnings Call Transcript

Foamix Pharmaceuticals (NASDAQ:FOMX) Q4 2018 Results Earnings Conference Call March 1, 2019 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Officer Iain Stuart - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Ken Cacciatore - Cowen and Company Sudan Loganathan - Cantor Fitzgerald Patrick Dolezal - LifeSci Capital Op...

185
MarketBeatFeb 26

Stock Price, News, & Analysis for Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-sev...

17
Yahoo FinanceFeb 21

Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know

The market expects Foamix (FOMX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

0

Earnings

-$0.69
-$0.53
-$0.36
-$0.20
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.